These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9051339)

  • 1. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data.
    Messori A
    Comput Methods Programs Biomed; 1997 Mar; 52(3):157-64. PubMed ID: 9051339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.
    Messori A
    Ann Oncol; 1998 Apr; 9(4):389-96. PubMed ID: 9636829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.
    Trippoli S; Becagli P; Messori A
    Eur J Clin Pharmacol; 1997; 53(3-4):281-2. PubMed ID: 9476047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Trippoli S; Becagli P; Tendi E
    Cancer; 1996 Dec; 78(11):2366-73. PubMed ID: 8941008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review).
    Messori A; Trippoli S
    Oncol Rep; 1999; 6(5):1135-41. PubMed ID: 10425315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Messori A; Bonistalli L; Costantini M; Trallori G; Tendi E
    J Clin Gastroenterol; 1996 Dec; 23(4):269-74. PubMed ID: 8957728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incremental cost effectiveness of multifocal cataract surgery].
    Pagel N; Dick HB; Krummenauer F
    Klin Monbl Augenheilkd; 2007 Feb; 224(2):101-9. PubMed ID: 17309005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
    Messori A; Trippoli S; Becagli P; Tendi E
    Anticancer Drugs; 1998 Jul; 9(6):491-502. PubMed ID: 9877236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
    Messori A; Becagli P; Berto V; Trippoli S; Font M; Tosolini F; Venturini F; Martini N
    Ann Pharmacother; 1997 Dec; 31(12):1447-54. PubMed ID: 9416379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.